Probiotics for the treatment of hyperlipidemia: Focus on gut-liver axis and lipid metabolism

Pharmacological Research, Journal Year: 2025, Volume and Issue: 214, P. 107694 - 107694

Published: March 10, 2025

Language: Английский

Alleviating effect of Lactobacillus fermentum E15 on hyperlipidemia and hepatic lipid metabolism in zebrafish fed by a high-fat diet through the production of short-chain fatty acids

Frontiers in Nutrition, Journal Year: 2025, Volume and Issue: 12

Published: March 3, 2025

Introduction Hyperlipidemia is regarded as one of the crucial factors leading to atherosclerosis and other cardiovascular diseases. Gut microbiota plays an important role in regulating host lipid metabolism. Nevertheless, exact mechanisms behind this remain unclear. Methods In present study, a hyperlipidemic zebrafish model was established using high-cholesterol diet (HCD) evaluate anti-hyperlipidemic effects Lactobacillus fermentum E15 ( L. E15). Results showed that effectively reduced accumulation blood vessels liver HCD-fed larvae. Meanwhile, improved abnormal levels, normalized enzyme activity. Real-time quantitative polymerase chain reaction (RT-qPCR) analysis revealed downregulated expression sterol regulatory element-binding factor (SREBP-1), peroxisome proliferator-activated receptor-gamma (PPAR- γ ), fatty acid synthase (Fasn), while upregulated receptor-alpha α ). Additionally, metabolomic produced series short-chain acids (SCFAs), including acetic acid, propionic butyric isovaleric acid. Notably, contributed reduction droplet contrast, blocking G-protein coupled receptor 43 (GPR43) with pertussis toxin (PTX) abolished on reducing RT-qPCR results further suggested both promoted GPR43 leptin A, which inhibited by PTX. Conclusion These findings alleviates HCD-induced hyperlipidemia activating through SCFAs.

Language: Английский

Impact of Gut Microbiome Interventions on Glucose and Lipid Metabolism in Metabolic Diseases: A Systematic Review and Meta-Analysis

Life, Journal Year: 2024, Volume and Issue: 14(11), P. 1485 - 1485

Published: Nov. 14, 2024

Background: The gut microbiome is increasingly recognized as a key player in metabolic health, influencing glucose and lipid metabolism through various mechanisms. However, the efficacy of microbiota-targeted interventions, such probiotics, prebiotics, fecal microbiota transplantation (FMT), diet-based treatments, remains unclear for specific outcomes. In this study, aim was to evaluate impact these interventions on parameters individuals with diseases diabetes mellitus (DM), obesity, syndrome. Methods: This systematic review meta-analysis included 41 randomized controlled trials that investigated effects treatments fasting glucose, glycated hemoglobin (HbA1c), homeostatic model assessment insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density (HDL-C), triglycerides. A comprehensive search conducted using databases like PubMed, Google Scholar, Scopus, focusing targeting microbiota. performed random-effects models, effect sizes calculated each outcome. Risk bias assessed Cochrane Bias tool. Results: Gut significantly reduced HbA1c, HOMA-IR, LDL-C, triglycerides, moderate heterogeneity observed across studies. also led modest increases HDL-C levels. Probiotic synbiotic showed most consistent benefits improving both profiles, while FMT yielded mixed results. Short-term rapid microbial shifts but less pronounced improvements, whereas longer-term had more substantial benefits. Conclusions: it demonstrated can improve outcomes, offering potential therapeutic strategy managing diseases. effectiveness varies depending type, duration, population characteristics, highlighting need further long-term studies assess sustained modulation health.

Language: Английский